FDA Approves New Therapy Option for Lung Cancer Patients Who Develop Resistance to Early Generation EGFR Inhibitors
DENVER – The International Association for the Study of Lung Cancer (IASLC) commends the U.S. Food and Drug Administration’s (FDA) decision to grant accelerated approval for osimertinib (TagrissoTM), an oral medication for advanced non-small cell lung cancer (NSCLC) patients with a specific epidermal growth factor receptor (EGFR) mutation (T790M) and following progression after previous EGFR inhibitor therapies.
DENVER – During November’s Lung Cancer Awareness Month, the International Association for the Study of Lung Cancer (IASLC) wants to highlight the importance of immunotherapy, a form of personalized medicine and a groundbreaking tool in the fight against lung cancer.
Sorafenib Modestly Increases Progression-Free Survival But Not Overall Survival in NSCLC Patients Who Failed Previous Therapies
DENVER – Sorafenib, a tyrosine kinase inhibitor (TKI) targeting the receptors for vascular endothelial growth factor, platelet derived growth factor, and mast/stem cell growth factor, modestly increases progression-free survival (PFS), time to progression, and disease control rate in non-small cell lung cancer (NSCLC) patients who have relapsed or failed two or three previous treatment regimens.
DENVER – November is Lung Cancer Awareness Month, but lung cancer does not have an awareness problem; lung cancer has a perception problem. What many people believe about lung cancer is inaccurate, and the International Association for the Study of Lung Cancer (IASLC) knows that if we can confront these myths, we can change misconceptions and help find cures for lung cancer.
DENVER, Colo. – The International Association for the Study of Lung Cancer (IASLC) recognizes the U.S. Food and Drug Administration’s (FDA) approval for another lung cancer immunotherapy agent (the second in two weeks) as a positive sign in the rapidly advancing science of lung cancer treatment. The last week the FDA approved nivolumab (Opdivo) to treat patients with advanced (metastatic) non-squamous non-small cell lung cancer (NSCLC) whose disease progressed during or after platinum-based chemotherapy. This is an extended approval of the use for nivolumab, as it was approved in March 2015 for squamous NSCLC in the same setting.
DENVER, Colo. – The International Association for the Study of Lung Cancer (IASLC) says the move by the U.S. Food and Drug Administration (FDA) to grant accelerated approval for a cutting-edge lung cancer treatment is a positive step forward that may help many patients improve their survival.